Q2 2026 revenue reached $29.8 million, led by e-commerce and international growth, with stable gross margins and a strong cash position. Expansion into skincare, IV/injection, and pharmaceuticals is underway, with major product launches and partnerships expected to drive growth in 2027.Based on Nia…
Q2 2026 saw $29.8M in net sales, 64.8% gross margin, and $1.0M net income, with strong cash reserves and no debt. Strategic growth included a successful skincare launch, telehealth expansion, and a new therapeutic candidate, while maintaining disciplined capital allocation.Original document: Niagen…
NAGE (Niagen Bioscience, Inc.) is set to announce its Q2'26 results on August 04, after the market closes. The earnings are expected to be disclosed at 4:02 PM ET (8:02 PM UTC).For Q2'26, revenue estimate is 30.53 million USD with EPS (earnings per share) anticipated at 0.01 USD. Learn more details…
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced the publication of a new peer-reviewed analysis of past clinical studies in Aging Cell examining the effects of Niagen® (patented ni…
Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that its Chief Executive Officer, Rob Fried, and Chief Financial Officer, Ozan Pamir, will participate in Canaccord Genuity’s 46th A…
The discussion highlighted the company's strategic move into pharmaceuticals with NB4168, a promising NAD analog for rare diseases and aging, supported by a world-class scientific team. Fiscal discipline and steady growth in core businesses remain priorities.Based on Niagen Bioscience, Inc. [NAGE…
Focused on rare genetic and aging-related disorders, the company is advancing NB4168, a highly bioavailable NAD+ precursor, for ataxia telangiectasia. Strong clinical evidence, a robust patent portfolio, and a platform strategy position it for premium rare disease market opportunities.Original docu…
Investors in Niagen Bioscience, Inc. NAGE need to pay close attention to the stock based on moves in the options market lately. That is because the Aug. 21, 2026 $12.50 Call had some of the highest implied volatility of all equity options today.What is Implied Volatility?Implied volatility shows ho…
